Enzon is selling below the break up value of its assets. Shedding one of the Peg programs will lighten up R&D expenses. This company seems to be restructuring into a full on oncology company. I still believe we may see a potential buyout or spinoff off these underappreciated oncology pipeline assets. I feel comfortable holdings here because of the companies cash position. If shares get cheaper, to me it would simply be a better bargain.